Mercury Metabolism by Bacteria in Humans

September 27, 2023 updated by: Matthew Rand, University of Rochester

Microbial Mechanisms of Methylmercury Metabolism in Humans

The purpose of this study is to evaluate how the bacteria in your gut can improve the break-down and de-toxification of non-harmful levels of a naturally occurring form of mercury (methylmercury) that comes with eating fish. This research could help scientists and doctors understand whether or not mercury in fish that we are likely to eat poses any concern for the health of people.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Completed

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

The overall objective of this study is to investigate the role of gut microbes in mediating how humans metabolize and excrete the environmental neurotoxicant methylmercury (MeHg). Exposure to MeHg through consumption of fish continues to pose a health risk for many populations globally. There remains considerable uncertainty in advising the public on mercury risks associated with fish consumption. A great deal of uncertainty stems from the fact that the MeHg metabolism and elimination rate is known to vary widely from individual to individual. This translates into the possibility that two individuals consuming the same amount of fish with the same frequency could, unknowingly, experience as much as 4-fold difference in accumulation of MeHg in their bodies. Thus, there is a need for greater understanding of the mechanisms of MeHg metabolism and elimination, as well as for development of tools to assess these characteristics in people. Our scientific premise is that symbiotic microbes in the human gut are required for the efficient biotransformation (demethylation) and excretion of toxic MeHg. In this prospective intervention study we will examine the variation in the rate at which MeHg is excreted, both between human subjects and within subjects over time, and relate it to the MeHg demethylation activity that is harbored in their respective gut microbes. Furthermore, through intervention with a prebiotic dietary supplement, we will induce a change in the gut microbial composition within the same individual and evaluate if slower of faster MeHg metabolism ensues. With these approaches we will obtain gut microbiome samples that correlate with faster or slower MeHg elimination kinetics. We then aim to identify specific genera and species of bacteria in the human gut responsible for MeHg metabolism. We will do this by feeding volunteers fish meals with documented trace levels of MeHg that are below any harmful level of exposure. We will subsequently measure kinetic rates of MeHg elimination via mass-spectrometry analysis of hair strands. We will also sample feces from the subjects as a source of the gut microbiota and as a medium to analyze the extent of MeHg metabolism (demethylation) that parallels its elimination. Study team members at Montana State University will directly examine the ability of the human gut microbiota to induce MeHg metabolizing activity in germ-free mice at rates that correspond with that seen in the human subject it was derived from. In parallel, we will use metagenomic sequence-informed strategies to bring isolated strains of the human gut bacteria to culture and subsequently interrogate their MeHg demethylating activity. We anticipate our results will lead to a clearer understanding of the microbial basis of human MeHg metabolism.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
36

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United States
    • New York
      • Rochester, New York, United States, 14642
        • University of Rochester Medical Center

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

18 years to 80 years (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • Subjects must be 18-80 years in age.
  • Subjects must be in good general health based on self-reported health status, with the exception of self-reported conditions listed in the exclusion criteria.
  • Subject must be willing to comply with study procedures.

Exclusion Criteria:

  • Known allergy to fish.
  • Pregnant or lactating women.
  • Use of hair dyes or chemical treatments within the prior month and/or intent to use such treatments during the two trial periods. (Hair treatment during the washout period up to one month prior to the second trial is acceptable).
  • Known gastrointestinal or renal disorders.
  • Subjects with diminished mental capacity.
  • Use of antibiotics within two months leading up to the study.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Basic Science
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: All Participants
All participant will eat 6 meals of tuna fish. All participants will take a prebiotic dietary supplement.
Other: Tuna fish
Six meals of tunafish (~200gms) will be consumed. Three meals will be consumed in a period of 14 days, and a subsequent 3 meals will be consumed within a 14 day period six month after the first 3 meals.
Dietary supplement: prebiotic
Prebiotin brand prebiotic will be consumed at 8grms/day for a period of 75 days. The prebiotic administration will begin with the second grouping of 3 fish meals.

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Mercury Elimination Rate Before Pre-biotic
Time Frame: 2.5 months
Mercury elimination rate will be determined for each individual at the beginning of the study, prior to any prebiotic administration. This determination will take place over the first 75 days of the study, wherein the first three fish meals are consumed, a eliminaiton period follows and then hair is sampled and analyzed. Time-resolved levels of mercury will be determined by longitudinal analysis of single hair strands using mass spectrometry methods. The values will be used to calculate the mercury elimination rate for each individual. The average elimination rate across the cohort before prebiotic will be reported. This total analysis will require approximately 2.5 months.
2.5 months
Mercury Elimination Rate After Pre-biotic
Time Frame: 11 months
Mercury elimination rate will be determined for each individual after commencing prebiotic self-administration for a period of 75 days, contemporaneously with the second set of fish meal consumption. This will begin approximately 6 months after the finish of the first round of fish meals and elimination (i.e. approximately 8.5 months after the participant starts the study). This second round will last approximately 2.5 months. Time-resolved levels of mercury will be determined by longitudinal analysis of single hair strands using mass spectrometry methods. The values will be used to calculate the mercury elimination rate for each individual. The average elimination rate across the cohort after prebiotic, from approximately 8.5 to 11 months will be reported.
11 months

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Change in Mercury Metabolism Ratio
Time Frame: Baseline to 10 months
Mercury metabolism ratio, i.e. conversion of methylmercury to inorganic mercury, will be determined for each individual before and after prebiotic administration. The difference in average metabolism ratio across the cohort before and after prebiotic will be reported. Mercury elimination ratios will be measured in stool samples using mass spectrometry methods.
Baseline to 10 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
University of Rochester

Collaborators

Collaborators

An organization other than the sponsor that provides support for a clinical study. This support may include activities related to funding, design, implementation, data analysis, or reporting.
National Institute of Environmental Health Sciences (NIEHS)

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
October 1, 2019

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
May 31, 2021

Study Completion (Actual)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
August 31, 2023

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
August 15, 2019

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
August 15, 2019

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
August 19, 2019

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
October 4, 2023

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
September 27, 2023

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
September 1, 2023

More Information

Terms related to this study

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • 3842
  • R01ES030940 (U.S. NIH Grant/Contract)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings